Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.53 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 13/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14842657 | 0.87 | MEN1 (0.60) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14854045 | 0.87 | MEN1 (0.60) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14842194 | 0.86 | MEN1 (0.58) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14842776 | 0.86 | KCNA5 (0.59) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14854003 | 0.86 | KCNA5 (0.59) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14842534 | 0.85 | MEN1 (0.57) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14853990 | 0.83 | PSEN1 (0.47) | MEN1KMT2ACXCR3PSEN1PSEN2 | |
| SCHEMBL14842203 | 0.82 | MEN1 (0.79) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14842546 | 0.82 | MEN1 (0.61) | MEN1KMT2ATAS2R14CXCR3PSEN1 | |
| SCHEMBL14853993 | 0.78 | KMT2A (0.42) | MEN1KMT2ATAS2R14CXCR3PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243374-A1 | Novel Sulfonamides | BRIGHAM & WOMENS HOSPITAL (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243374-A1 | Novel Sulfonamides | BRIGHAM & WOMENS HOSPITAL (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243374-A1 | Novel Sulfonamides | BRIGHAM & WOMENS HOSPITAL (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013052700-A1 | NOVEL SULFONAMIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243374-A1 | Novel Sulfonamides | BACE1, BACE2, GSAP | MEN1 2751/4885KMT2A 1573/4885TAS2R14 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.